Posters
« Back
Expression and purification of Active Recombinant HIV-1 Protease and the development of protease-based activity/inhibitor screening assays
EP27366
Poster Title: Expression and purification of Active Recombinant HIV-1 Protease and the development of protease-based activity/inhibitor screening assays
Submitted on 15 Mar 2018
Author(s): Santoshkumar L. Khatwani, Ph.D., Grigoriy Tchaga, Ph.D. and Gordon Yan, Ph.D.
Affiliations: BioVision Inc.
Poster Views: 859
View poster »


Poster Information
Abstract: Human Immunodeficiency Virus (HIV) is the cause of the Acquired Immunodeficiency
Syndrome (AIDS). HIV-1 protease (HIV-1 PR) is a retroviral aspartyl protease
(retropepsin) that is essential for the life-cycle of HIV. It cleaves newly synthesized viral
polyproteins at the appropriate places into functional protein products as mature
protein components of an infectious HIV virion. The mutation of HIV-1 PR's active site
or inhibition of its activity disrupts the ability of the virus to replicate and infect
additional cells. HIV-1 PR is considered an attractive target for designing inhibitors and
considerable focus has been put into its expression and purification in recombinant
form. The expression of HIV-1 PR in Escherichia coli has proven to be difficult due to
the issues related to its low expression, solubility and yields, which have limited the
development of HIV-1 PR-based activity/inhibitor screening assays. At BioVision, we
have successfully overcome these issues associated with HIV-1 PR by expressing it
as a GST-fusion protein in E. coli at relatively high yields of the purified fusion protein
(5-7 mg/L of cell culture). The purified protease is highly active and it was
successfully utilized in developing a protease-based assay using its proteolytic activity
against an HIV-1 PR-specific fluorogenic peptide substrate. The enzyme showed
characteristic inhibition of its specific proteolytic activity in the presence of an aspartyl
protease inhibitor (Pepstatin A). The HIV-1 PR assay is sensitive, simple, and highthroughput
adaptable. The assay provides a useful tool for screening of potential HIV-1
PR inhibitors for chemotherapeutic applications.
Summary: 1. HIV-1 PR was successfully expressed and purified as a GST-fusion protein in E. coli
at relatively high yields of the purified fusion protein (5-7 mg/L of cell culture).
2. Characterization of HIV-PR with a HIV-1 PR-specific substrate indicated a MichaelisMenten
Kinetics.
3. HIV-1 PR enzyme was successfully utilized to develop protease-based activity
assay and inhibitor screening kits.
4. HIV-1 PR assays are sensitive, simple, high-throughput adaptable
Report abuse »
Creative Commons

Related Posters


2D FT0ICR MS/MS analysis of IgG1
Johanna Paris 1 , Tomos E. Morgan 1 , Yuko P. Y. Lam 1 Christopher A. Wootton 1 Mark André Delsuc 2 , Mark P. Barrow 1 , John O’Hara 3 , and Peter B. O’Connor 1

Primary Human Hepatocytes 3D in vitro Culture Model for Studying Hepatic Function
Sujoy Lahiri, Julia Tritapoe, Kate Comstock, Michael F. Millett, Mark Kennedy, Theresa V. Nguyen, Deborah K. Tieberg, David T. Kuninger

TMT Quantification for Shotgun Proteomics on a Trapped-Ion-Mobility quadrupole-Time-Of- Flight mass spectrometer (TIMS-QTOF) powered by Parallel-Accumulation and Serial- Fragmentation (PASEF)
Matt Willetts1, Shourjo Ghose1 Heiner Koch2, Scarlet Koch2, Markus Lubeck2, Gary Kruppa1

Genetic Engineering in Male Sterility for Hybrid Variety Development
Abir Hasan Joy

Characterization of patient-derived organoids cultured on a gas-rich, liquid-liquid interface
James T. Shoemaker, Katherine R. Richardson, Jamie Arnst, Adam Marcus, Jelena Vukasinovic